Corcept Therapeutics (NASDAQ:CORT) Trading 6% Higher – Should You Buy?

Posted by Stanley Muller on Jul 25th, 2026

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) were up 6% on Thursday . The stock traded as high as $96.55 and last traded at $96.3520. Approximately 341,384 shares traded hands during trading, a decline of 79% from the average daily volume of 1,589,304 shares. The stock had previously closed at $90.88.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. UBS Group set a $135.00 target price on Corcept Therapeutics in a research note on Thursday, May 28th. Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Piper Sandler raised their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Finally, Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.83.

Get Our Latest Analysis on CORT

Corcept Therapeutics Trading Down 1.3%

The company has a market capitalization of $10.24 billion, a P/E ratio of 272.46 and a beta of 0.47. The stock has a 50 day moving average price of $80.40 and a 200 day moving average price of $54.47.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The company’s revenue was up 4.9% on a year-over-year basis. On average, research analysts predict that Corcept Therapeutics Incorporated will post 0.53 EPS for the current year.

Insider Activity

In other news, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total transaction of $832,000.00. Following the sale, the director directly owned 1,094,543 shares in the company, valued at approximately $91,065,977.60. The trade was a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Atabak Mokari sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $81.15, for a total value of $3,246,000.00. Following the completion of the transaction, the chief financial officer directly owned 16,130 shares of the company’s stock, valued at $1,308,949.50. This represents a 71.26% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 300,000 shares of company stock valued at $22,088,050. 20.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. First Trust Advisors LP raised its stake in shares of Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after acquiring an additional 1,480,059 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after purchasing an additional 1,274,215 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Corcept Therapeutics by 38.0% in the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares during the last quarter. Norges Bank acquired a new stake in Corcept Therapeutics in the fourth quarter valued at $24,213,000. Finally, UBS Group AG increased its holdings in Corcept Therapeutics by 413.8% in the third quarter. UBS Group AG now owns 549,938 shares of the biotechnology company’s stock valued at $45,705,000 after purchasing an additional 442,898 shares during the period. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.